Much of the hopes for precision medicine (as outlined Dr. Dr. Collins) are based on deriving large amounts of genomic, proteomic, epigenomic and metabolomic data on large cohorts of patients. It will take decades to build these cohorts and even more time to analyze them and derive specific conclusions on how these will help individualize treatments.
However, there is a pressing need for how to individualize contemporary clinical practices even in the absence of large-scale "Omics" analyses. Current guidelines often recommend treatments based on cardiovascular risk calculators but they do not really take into account the individual risk of side effects.
How can we individualize guideline-based treatment recommendations?